ABVX

Abivax
ABVX

Overview Fund Trends Analyst Outlook Journalist POV
92.91 USD
--2.70
2.82%
At close Updated Oct 16, 4:00 PM EDT
Pre-market
After hours
92.34
--0.57
0.61%
1 day
-2.82%
5 days
-0.85%
1 month
12.92%
3 months
840.38%
6 months
1,377.11%
Year to date
1,174.49%
1 year
817.18%
5 years
1,019.4%
10 years
1,019.4%
 

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Employees: 69

Healthcare Biotechnology
0
Funds holding %
of 7,495 funds
Explore Fund Trends
0
Analysts bullish %
of 8 analysts
See Analyst Outlook
0
Positive news %
of 7 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™